FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and can be used for treating hypogonadotropic hypogonadism in patients. That is ensured by administering gonadorelin acetate intranasally in dose of 1–20 mcg in pulsed mode once every 60–90 minutes. Also disclosed are a method of administering gonadorelin acetate and a spray for treating hypogonadotropic hypogonadism.
EFFECT: group of inventions provides treating hypogonadotropic hypogonadism by administering gonadorelin acetate in a low dosage in the form of spray intranasally in pulsed mode, providing the active substance delivery within the framework of physiological secretion.
3 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PREDICTION OF CLINICAL EFFECTIVENESS OF TREATMENT WITH CHORIONIC GONADOTROPIN IN MALES WITH HYPOGONADISM | 2015 |
|
RU2604681C1 |
| METHOD FOR TREATMENT OF ADOLESCENT HYPOGONADOTROPIC HYPOGONADISM IN EXPERIMENT | 2020 |
|
RU2750713C1 |
| METHOD OF TREATING SECONDARY HYPOGONADISM IN MALES | 1995 |
|
RU2117446C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF PITUITARY INCIDENTALOMA | 2023 |
|
RU2822656C1 |
| METHOD FOR PREDICTING PARTIAL AGE-CAUSED ANDROGENIC DEFICIENCY (PADAM) | 2002 |
|
RU2231289C2 |
| METHOD FOR INTEGRATED TREATMENT OF MALE NORMOGONADOTROPIC INFERTILITY | 2012 |
|
RU2480256C1 |
| DIAGNOSTIC METHOD OF CENTRAL HYPOGONADISM IN FEMALES | 2019 |
|
RU2710539C1 |
| METHOD FOR DETERMINING THE AGING STAGE OF THE REPRODUCTIVE SYSTEM IN CENTRAL FEMALE HYPOGONADISM | 2019 |
|
RU2714681C1 |
| METHOD FOR PREDICTING THE MANIFESTATION OF HYPOGONADISM IN MEN | 2022 |
|
RU2786597C1 |
| METHOD FOR TREATING CRYPTORCHISM IN COMBINATION WITH SECONDARY HYPOGONADISM | 2000 |
|
RU2192169C2 |
